Founder and Partner, Katana Capital
Charlie is a founding partner of Katana Capital, he also sits on the board of directors at Proteus Digital Health and runs the Songhurst Group. Beforehand, Charlie ran Corporate Strategy at for Microsoft and was employed as an analyst at McKinsey & Company.Charlie graduated from The University of Oxford with a Bachelor’s degree in Politics, Philosophy and Economics.
Chief Product Officer, Proteus Digital Health
David is Chief Product Officer at Proteus Digital Health, previously at Proteus David was Senior Vice President, Corporate Development. At Catalyst Biosciences David was President, he was also Chief Business Officer and part of the founding team at Iconix Biosciences. David attended Wesleyan University and holds an M.B.A. from the Harvard Business School.
General Partner & Chief Medical Officer at Frost Data Capital
Jack is a founding member of the Centre for Health and Human Performance (CHHP) where he leads health optimisation and specialist medicine services. Jack graduated with degrees in Medicine and Physiology from UCLH (London), he is a high altitude medicine specialist. Jack is also an entrepreneur of medical technology, including bio-sensors and artificial intelligence.
Consul and Acting Head of Trade & Investment
Samantha is currently Consul and Acting Head of Trade & Investment at the British Consulate-General San Francisco where she leads a 13 strong trade and investment team focused on international business development in creative & digital media, life science, healthcare, renewable energy, software, and communications sectors. Samantha began her career in the private sector in Manchester in recruitment (2006), before working for a Social Entrepreneur (2010) whose ambition was to encourage children from deprived backgrounds to choose careers within the technology sector.
Entrepreneur and consultant
Carina is an entrepreneur with extensive experience in launching and commercializing technical projects in Silicon Valley. Most recently she co-founded HelixNano – a company innovating at the intersection of software and biotechnology. HelixNano is leveraging recent advances in DNA sequencing and machine learning to develop ‘The Molecular Recorder’. Prior to her Silicon Valley experience, Carina advised on deals in the technology and biotechnology sectors as a financial analyst at Goldman Sachs in London. Carina read PPE at Oxford University.